PureTech Health
PRTC · Main Market · Health Care · mcap £262m · 111.0p
PureTech founds and part-owns biotech companies, developing some programmes itself before spinning them into separate 'Founded Entities' funded by outside investors. It earns returns through equity stakes, milestones and royalties.
Positive 7 Oct 2026
Briarwood Chase rose above 10% and Tang Capital to 7.08%Two holders built stakes over the past year. 7 Oct 2026 25 Sep 2026 8 May 2026
Positive 22 Sep 2026
Management pledges greater capital returns from future proceedsCash of $220m and a leaner cost base after Celea financing. 22 Sep 2026 29 Apr 2026
Positive 22 Sep 2026
Seaport stake valued at about $360m after Nasdaq IPOListed holding value is well above book value shown in accounts, though not stated. 22 Sep 2026
Positive 9 Jul 2026
Directors and PDMRs bought shares in September 2025 and July 2026Repeated insider purchases including the CEO as shares weakened. 9 Jul 2026 24 Sep 2025
Mixed 29 Apr 2026
Voluntary Nasdaq delisting and cost reductionConcentrates on London listing and a leaner hub. 29 Apr 2026
- 2026-07-02 acquisition · $30m – PureTech invested $30m in Celea's $180m financing, holding 35.4%; reserved $70m further 2 Jul 2026
- 2024-06-24 tender offer · $100m – Repurchased 31.5m shares at 250 pence per share, completing tender offer; shares cancelled 24 Jun 2024
- 2024-02-07 buyback programme · $50m – Share buyback programme completed 28 Aug 2024
From the company's own announcements · not investment advice
Company filings. Not investment advice.